TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17461719
Drug: lopinavir/ritonavir 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir 400/100 mg twice-daily or 800/200 mg once-daily without gastric acid-reducing agents
Study: 15610362
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose birch pollen exposure during pregnancy
Study: 15610362
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose birch pollen exposure during pregnancy
Study: 11310807
Drug: Amoxicillin-clavulanate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate (2 g/200 mg/8 hr)
Study: 11310807
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 g/24 hr)
Study: 8389105
Drug: ICI 204,219
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 204,219 (200 micrograms/puff, total dose 1,600 micrograms)
Study: 27472878
Drug: Crocus sativus
Normalized name: CROCUS SATIVUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocus sativus L.
Study: 22325963
Drug: Multimodal periarticular
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimodal periarticular soft tissue injection
Study: 17280925
Drug: 0.4 ml
Normalized name: ethanol 0.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 ml fentanyl 0.05 mg/ml
Study: 17280925
Drug: 0.4 ml
Normalized name: ethanol 0.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 ml mepivacaine with epinephrine 1:200,000
Study: 15663351
Drug: Rasagiline 1
Normalized name: rasagiline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 1 or 2mg once daily
Study: 15663351
Drug: Rasagiline 0.5
Normalized name: rasagiline 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 0.5 or 1mg once daily
Study: 15663351
Drug: Rasagiline 1mg
Normalized name: Rasagiline 1mg Oral tablet
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rasagiline 1mg once daily
Study: 15663351
Drug: Rasagiline (monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline (monotherapy and combination therapy)
Study: 9988823
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (15 mg)
Study: 1575174
Drug: Nifedipine SR
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine SR 50 mg
Study: 1575174
Drug: Nifedipine SR
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine SR 100 mg
Study: 1575174
Drug: Nifedipine SR
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine SR 150 mg
Study: 30169375
Drug: Concurrent pictorial
Normalized name: influenza B virus B/Victoria/705/2018 antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent pictorial drug choice task (smoking vs. not smoking)
Study: 30169375
Drug: Concurrent pictorial
Normalized name: influenza B virus B/Victoria/705/2018 antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent pictorial drug choice task (alcohol vs. food)
Study: 18773262
Drug: 0.25% nipradilol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% nipradilol, twice daily for 3 years
Study: 18773262
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol ophthalmic solution, twice daily for 3 years
Study: 14669936
Drug: Antioxidant vitamin
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamin supplement (18 mg beta‐carotene, 900 mg vitamin C, 90 mg vitamin E)
Study: 14669936
Drug: Antioxidant vitamin
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamin supplement
Study: 8705154
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg intra-articular morphine in 15 ml isotonic saline
Study: 8705154
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg intravenous morphine in 10 ml isotonic saline
Study: 2371491
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 500 mg/day for 3 days
Study: 22420837
Drug: Conventional antiseptic
Normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antiseptic (polyhexanide solution) dressings
Study: 19486346
Drug: m-TOR inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-TOR inhibitor sirolimus (SRL)
Study: 16855426
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch (4 mg/24 h starting dose, increased by 4 mg/24 h weekly)
Study: 16855426
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch (4 mg/24 h starting dose, increased by 2 mg/24 h weekly)
Study: 16855426
Drug: Fast-titration regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-titration regimen of rotigotine
Study: 16855426
Drug: Slow-titration regimen
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-titration regimen of rotigotine
Study: 12944032
Drug: Nisoldipine ER
Normalized name: nisoldipine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine ER (20 to 60 mg once daily)
Study: 12944032
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 to 10 mg once daily)
Study: 9088588
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg twice daily for 14 days)
Study: 8491252
Drug: Atenolol 150
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol 150 mg
Study: 26322917
Drug: Omega 3
Normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omega 3 fatty acid (O3FA) oral supplement (2,400 mg/day) for 45 days
Study: 26322917
Drug: Placebo (olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (olive oil, 8 capsules)
Study: 23695483
Drug: Escitalopram (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (5 mg/d titrated to 20 mg/d over 6 weeks)
Study: 18261166
Drug: EPA (eicosapentaenoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA (eicosapentaenoic acid) 1800 mg daily from day 4 to day 14
Study: 16173532
Drug: External Qi
Normalized name: San Qi Root
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External Qi therapy (EQT)
Study: 12921918
Drug: Selegiline 5
Normalized name: selegiline 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline 5 mg/day (under 5 years) and 10 mg/day (over 5 years)
Study: 21416235
Drug: Methylphenidate 1
Normalized name: methylphenidate 17.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 1 mg/kg/day
Study: 10937097
Drug: Carbon dioxide
Normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbon dioxide laser treatment alone
Study: 10937097
Drug: Carbon dioxide
Normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbon dioxide laser treatment followed by erbium:YAG laser treatment
Study: 10937097
Drug: Erbium:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erbium:YAG laser treatment alone
Study: 10937097
Drug: Erbium:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erbium:YAG laser treatment followed by carbon dioxide laser treatment
Study: 10937097
Drug: Untreated skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untreated skin subjected to laser treatment
Study: 8669575
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml bupivacaine 0.5% + 25 mg (0.5 ml) ketamine + 1 in 200,000 adrenaline
Study: 8669575
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml bupivacaine 0.5% + 0.5 ml 0.9% saline + 1 in 200,000 adrenaline
Study: 6721765
Drug: Half-strength povidone-iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half-strength povidone-iodine (Betadine) solution
Study: 11531671
Drug: 5000 U
Normalized name: lipase 5000 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 U unfractionated heparin subcutaneously after surgery
Study: 11531671
Drug: 7500 U
Normalized name: amylase 97500 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7500 U unfractionated heparin subcutaneously after surgery
Study: 11531671
Drug: 10,000 U
Normalized name: Erwinaze 10,000 UNT Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10,000 U unfractionated heparin subcutaneously after surgery
Study: 7985709
Drug: Low-dose amphotericin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amphotericin B (0.1 mg/kg per day)
Study: 29208686
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) administration (20 μg/kg sc 3×/week) for 26 weeks
Study: 24693681
Drug: Antioxidant nutrients
Normalized name: CertaVite Senior with Antioxidant Nutrients Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant nutrients supplement (AO) for 5 days prior to surgery
Study: 24693681
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CT) with no supplement
Study: 19546522
Drug: Ciclosporine (CsA)
Normalized name: ciclosporin
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ciclosporine (CsA) 2.5 mg/kg body weight
Study: 10535855
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 2 g daily
Study: 15474755
Drug: CE/MPA (conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE/MPA (conjugated estrogen 0.625 mg + medroxyprogesterone acetate 5 mg)
Study: 15474755
Drug: E2/NETA (17‐beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/NETA (17‐beta‐estradiol 2 mg + norethisterone acetate 1 mg)
Study: 2436359
Drug: Glycerol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol therapy
Study: 2436359
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of glycerol and dextran
Study: 28826262
Drug: Topical propolis
Normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical propolis ointment (5%; twice daily)
Study: 28826262
Drug: Conventional therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapies alone
Study: 24841843
Drug: Cocaine exposure
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine exposure (40 mg, IV)
Study: 17418537
Drug: 5HT2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5HT2 receptor antagonists (trazodone or nefazodone)
Study: 8666860
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg aerosolized pentamidine (AP) once-monthly
Study: 8666860
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg aerosolized pentamidine (AP) twice-monthly
Study: 2134327
Drug: IdB 1027
Approvals — FDA: no, EMA: no, PMDA: no
Description: IdB 1027 (600 mg b.i.d.) for 10 days
Study: 474432
Drug: Intravenous disopyramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous disopyramide
Study: 54578
Drug: Oral disopyramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral disopyramide
Study: 30892810
Drug: 2RDA (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2RDA (1.6 g kg‐1 day‐1)
Study: 30892810
Drug: RDA (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: RDA (0.8 g kg‐1 day‐1)
Study: 25794201
Drug: Ultrasound-guided greater
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided greater occipital nerve block (GONB) with bupivacaine 0.5% (1.5 mL)
Study: 25794201
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline 0.9% 1.5 mL)
Study: 24437202
Drug: Ozonotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozonotherapy and klimadynon (herbal medicine with estrogen-like action)
Study: 21719111
Drug: Adjunctive clonazepam
Normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive clonazepam
Study: 19301038
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (CaCO3) therapy
Study: 19301038
Drug: Sevelamer therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevelamer therapy
Study: 10570386
Drug: Low-dose narrow-band
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose narrow-band UVB phototherapy with calcipotriol ointment (50 microg/g) applied twice daily
Study: 10570386
Drug: Low-dose narrow-band
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose narrow-band UVB phototherapy without calcipotriol ointment
Study: 8673999
Drug: Adoptive immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive immunotherapy (AI) with tumor-infiltrating lymphocytes (TIL) and recombinant interleukin-2 (rIL-2)
Study: 8673999
Drug: Adoptive immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive immunotherapy (AI)
Study: 1651060
Drug: Pentostam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentostam (20 mg Sb/kg/day intramuscularly for 20 days)
Study: 1651060
Drug: Allopurinol ribonucleoside
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol ribonucleoside (1,500 mg QID) plus probenecid (500 mg QID) for 28 days
Study: 25669614
Drug: L-Polamidon® 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Polamidon® 5 mg tablets (test)
Study: 25669614
Drug: L-Polamidon® solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Polamidon® solution for substitution (reference)
Study: 21898754
Drug: Oral anti-diabetes
Normalized name: Diabetic Tussin EX Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anti-diabetes drugs + basal insulin
Study: 21898754
Drug: Oral anti-diabetes
Normalized name: Diabetic Tussin EX Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anti-diabetes drugs alone
Study: 18977068
Drug: Pitavastatin (P)
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin (P) therapy
Study: 7619664
Drug: desipramine 100
Normalized name: desipramine 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: desipramine 100 mg
Study: 7619664
Drug: reboxetine 4
Normalized name: reboxetine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: reboxetine 4 mg
Study: 2228340
Drug: Digoxin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (mean maintenance daily dose of 0.30 +/- 0.03 mg)
Study: 154426
Drug: Oxamethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxamethacin (100 mg b.i.d.)
Study: 30573506
Drug: Mogamulizumab 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mogamulizumab 1.0 mg/kg once weekly for 4 weeks and biweekly thereafter
Study: 30573506
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice of chemotherapy
Study: 25782428
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g low-fat milk powder (active control group)
Study: 23562197
Drug: MFNS +
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFNS + OXY3 (200 μg MFNS q.d. + 3 sprays/nostril of OXY 0.05%)
Study: 23562197
Drug: MFNS +
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFNS + OXY1 (200 μg MFNS q.d. + 1 spray/nostril of OXY)
Study: 18924387
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and alternative therapies
Study: 15226336
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin (HDPEB) 40 mg/m² on days 1 through 5
Study: 15226336
Drug: Standard-dose cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose cisplatin (PEB) 20 mg/m² on days 1 through 5
Study: 15226336
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin (HDPEB)
Study: 15226336
Drug: Standard-dose cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose cisplatin (PEB)
Study: 27196121
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine (1 μg∙kg‐1)
Study: 22614545
Drug: Sustained-release bupropion
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release bupropion (Bup-SR) for 8 weeks
Study: 18349557
Drug: Standard 1-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 1-week triple therapy followed by omeprazole (20 mg, qd) for 3 weeks (group A)
Study: 18349557
Drug: Standard 1-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 1-week triple therapy only (group B)
Study: 18349557
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg, qd) for 3 weeks followed by 1-week triple therapy (group C)
Study: 14696468
Drug: Low-dose anticancer
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose anticancer drugs (Group A, n = 40)
Study: 14696468
Drug: Conventional-dose anticancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose anticancer drugs (Group B, n = 42)
Study: 9876959
Drug: eptastigmine 15
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: eptastigmine 15 mg t.i.d.
Study: 9876959
Drug: eptastigmine 10
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: eptastigmine 10 mg t.i.d.
Study: 9876959
Drug: eptastigmine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: eptastigmine (both doses) in severely impaired patients (n=222)
Study: 7907054
Drug: PGE2 tablets
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 tablets (n = 106)
Study: 7011011
Drug: Ibuprofen (Motrin)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (Motrin)
Study: 19405015
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with infliximab (administered at weeks 4, 6, 10, and then every 6 weeks)
Study: 19405015
Drug: On-demand treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand treatment with infliximab (administered at weeks 4, 6, 10 and then upon symptom recurrence)
Study: 17316832
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for 5 days post-operatively
Study: 17316832
Drug: Ciprodex treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprodex treatment
Study: 2883488
Drug: Chloroquine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (300 mg base weekly)
Study: 9645872
Drug: Primaquine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine (0.5 mg base/kg daily)
Study: 7837323
Drug: i.v. Tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. Tramadol (1 mg/Kg)
Study: 7837323
Drug: Distilled water
Normalized name: Distilled Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water (20 ml) - Control group
Study: 2967164
Drug: Combined beta‐agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined beta‐agonist and anticholinergic preparation (fenoterol hydrobromide 200 micrograms and ipratropium bromide 80 micrograms)
Study: 29187242
Drug: Therapeutic cooling
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic cooling plus best medical treatment
Study: 9425972
Drug: Mepivacaine (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine (1.4 mg/kg in 40 mL)
Study: 30043250
Drug: Headache scores
Approvals — FDA: no, EMA: no, PMDA: no
Description: Headache scores at 4 h post-dose
Study: 30043250
Drug: Headache scores
Approvals — FDA: no, EMA: no, PMDA: no
Description: Headache scores at 2 h post-dose
Study: 15352918
Drug: Amitriptyline (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (80 mg)
Study: 7491877
Drug: Fluoxetine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (40 mg)
Study: 8304306
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg famotidine at 8:30 AM
Study: 8304306
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg famotidine at 10 PM
Study: 2724250
Drug: 5 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/m2 oral weekly methotrexate (MTX)
Study: 2724250
Drug: 10 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/m2 oral weekly methotrexate (MTX)
Study: 29390150
Drug: RV1 (monovalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV1 (monovalent rotavirus vaccine)
Study: 24675993
Drug: Ethanol lock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol lock therapy (E-Lock)
Study: 18042505
Drug: Low-dose salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose salmon oil (1 g tid for 24 weeks)
Study: 18042505
Drug: Crossover to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover to salmon oil treatment (from CT-SO to SO)
Study: 18042505
Drug: Low-dose salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose salmon oil (3 g/day)
Study: 17065044
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (vitamins A 1000 IU, B6 2.2 mg, B12 2.2 microg, C 200 mg, E 400 IU, folic acid 400 microg, N-acetylcysteine 200 mg, Cu 2 mg, Zn 15 mg, Mn 0.5 mg, Fe 30 mg, calcium 800 mg, selenium 100 microg)